Etrasimod
Författaruppgift saknas
Journal missing · review PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för etrasimod. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
27 hitsEfficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.
Peyrin-Biroulet L, Dubinsky MC, Sands BE, Panés J, Schreiber S, Reinisch W, Feagan BG, Danese S, Yarur AJ, D'Haens GR, Goetsch M, Wosik K, Keating M, Lazin K, Wu J, Modesto I, McDonnell A, Bartolome L, Vermeire S.
J Crohns Colitis · clinical trial, phase iii; research-article; randomized controlled trial; journal article · DOI 10.1093/ecco-jcc/jjae038Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial.
Yarur AJ, Chiorean MV, Panés J, Jairath V, Jairath V, Zhang J, Rabbat CJ, Sandborn WJ, Vermeire S, Peyrin-Biroulet L.
J Crohns Colitis · clinical trial, phase ii; research-article; randomized controlled trial; journal article · DOI 10.1093/ecco-jcc/jjae007A practical guide to selecting and using new ulcerative colitis therapies.
Nagaraj T, Shinn J, De Felice K.
Curr Opin Gastroenterol · review; journal article · DOI 10.1097/mog.0000000000001023Cardiovascular Evaluation of Etrasimod, a Selective Sphingosine 1-phosphate Receptor Modulator, in Healthy Adults: Results of a Randomized, Thorough QT/QTc Study.
Darpo B, Connor K, Cabell CH, Grundy JS.
Clin Pharmacol Drug Dev · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1002/cpdd.1388Safety, Pharmacokinetics, and Pharmacodynamics of Etrasimod: Single and Multiple Ascending Dose Studies in Healthy Adults.
Lee CA, Schreiber S, Bressler B, Adams JW, Oh DA, Tang YQ, Zhang J, Komori HK, Grundy JS.
Clin Pharmacol Drug Dev · research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1002/cpdd.1379Etrasimod: First Approval.
Shirley M.
Drugs · review; journal article · DOI 10.1007/s40265-024-01997-7Etrasimod: A Sphingosine-1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis.
Choi D, Becker M, Ivanov M, Bhat S.
Ann Pharmacother · review; journal article · DOI 10.1177/10600280231225770Etrasimod for ulcerative colitis: evaluating phase III results.
Matsuoka K, Hibi T.
Nat Rev Gastroenterol Hepatol · comment; journal article · DOI 10.1038/s41575-023-00793-0Author Correction: Etrasimod for ulcerative colitis: evaluating phase III results.
Matsuoka K, Hibi T.
Nat Rev Gastroenterol Hepatol · published erratum · DOI 10.1038/s41575-023-00817-9Etrasimod (Velsipity) for ulcerative colitis.
Författaruppgift saknas
Med Lett Drugs Ther · journal article · DOI 10.58347/tml.2023.1690bDesign and synthesis of etrasimod derivatives as potent antibacterial agents against Gram-positive bacteria.
Zore M, San-Martin-Galindo P, Reigada I, Hanski L, Fallarero A, Yli-Kauhaluoma J, Patel JZ.
Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2023.115921In moderately to severely active UC, etrasimod increased remission at 12 and 52 wk but increased adverse events.
Al-Jabri R, Afif W.
Ann Intern Med · comment; journal article · DOI 10.7326/j23-0048Etrasimod in Ulcerative Colitis.
Ghoneim S.
Gastroenterology · journal article · DOI 10.1053/j.gastro.2023.05.006Disposition and Mass Balance of Etrasimod in Healthy Subjects and In Vitro Determination of the Enzymes Responsible for Its Oxidative Metabolism.
Lee CA, Oh DA, Tang Y, Yi P, Bashir M, English S, Croft M, Blackburn A, Bloom S, Gilder K, Grundy JS.
Clin Pharmacol Drug Dev · research support, non-u.s. gov't; journal article · DOI 10.1002/cpdd.1255Efficacy of Etrasimod on Symptomatic Relief in Patients With Ulcerative Colitis: An Analysis of the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 Trials.
Författaruppgift saknas
Gastroenterol Hepatol (N Y) · other; journal articleThe sphingosine-1-phosphate receptor agonist etrasimod in ulcerative colitis.
Atreya R, Neurath MF.
Lancet · comment; journal article · DOI 10.1016/s0140-6736(23)00228-3Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
Sandborn WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, Panes J, Yarur A, Ritter T, Baert F, Schreiber S, Sloan S, Cataldi F, Shan K, Rabbat CJ, Chiorean M, Wolf DC, Sands BE, D'Haens G, Danese S, Goetsch M, Feagan BG.
Lancet · randomized controlled trial; journal article · DOI 10.1016/s0140-6736(23)00061-2Etrasimod for the treatment of ulcerative colitis.
Wils P, Peyrin-Biroulet L.
Immunotherapy · review; journal article · DOI 10.2217/imt-2022-0255Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE).
Silverberg JI, Bissonnette R, Kircik L, Murrell DF, Selfridge A, Liu K, Ahluwalia G, Guttman-Yassky E.
J Eur Acad Dermatol Venereol · clinical trial, phase ii; randomized controlled trial; journal article · DOI 10.1111/jdv.18914Etrasimod 2 mg Once Daily as Treatment for Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 Trials.
Författaruppgift saknas
Gastroenterol Hepatol (N Y) · research-article; journal articleRepurposing the Sphingosine-1-Phosphate Receptor Modulator Etrasimod as an Antibacterial Agent Against Gram-Positive Bacteria.
Zore M, Gilbert-Girard S, San-Martin-Galindo P, Reigada I, Hanski L, Savijoki K, Fallarero A, Yli-Kauhaluoma J, Patel JZ.
Front Microbiol · research-article; journal article · DOI 10.3389/fmicb.2022.926170Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study.
Vermeire S, Chiorean M, Panés J, Peyrin-Biroulet L, Zhang J, Sands BE, Lazin K, Klassen P, Naik SU, Cabell CH, Sandborn WJ.
J Crohns Colitis · research-article; randomized controlled trial; journal article · DOI 10.1093/ecco-jcc/jjab016P045 Effect of Etrasimod on Circulating Lymphocyte Subsets: Data From a Randomized Phase 1 Study in Healthy Japanese and Caucasian Men.
Kiyomi K, Caroline L, Lisette A, Kye G, John G.
Am J Gastroenterol · journal article · DOI 10.14309/01.ajg.0000722976.59079.27Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis.
Sandborn WJ, Peyrin-Biroulet L, Zhang J, Chiorean M, Vermeire S, Lee SD, Kühbacher T, Yacyshyn B, Cabell CH, Naik SU, Klassen P, Panés J.
Gastroenterology · clinical trial, phase ii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1053/j.gastro.2019.10.035The Selective Sphingosine 1-Phosphate Receptor Modulator Etrasimod Regulates Lymphocyte Trafficking and Alleviates Experimental Colitis.
Al-Shamma H, Lehmann-Bruinsma K, Carroll C, Solomon M, Komori HK, Peyrin-Biroulet L, Adams J.
J Pharmacol Exp Ther · research support, non-u.s. gov't; journal article · DOI 10.1124/jpet.118.254268Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor.
Buzard DJ, Kim SH, Lopez L, Kawasaki A, Zhu X, Moody J, Thoresen L, Calderon I, Ullman B, Han S, Lehmann J, Gharbaoui T, Sengupta D, Calvano L, Montalban AG, Ma YA, Sage C, Gao Y, Semple G, Edwards J, Barden J, Morgan M, Chen W, Usmani K, Chen C, Sadeque A, Christopher RJ, Thatte J, Fu L, Solomon M, Mills D, Whelan K, Al-Shamma H, Gatlin J, Le M, Gaidarov I, Anthony T, Unett DJ, Blackburn A, Rueter J, Stirn S, Behan DP, Jones RM.
ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/ml500389m